Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.4K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

619
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
619
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

330
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
330
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

323
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
323
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

366
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
366
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

366
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
366

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New proteomic biomarkers identified in plasma extracellular vesicles in sarcoidosis: a case-control matched study.

Frontiers in immunology·2026
Same author

Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment.

Autoimmunity reviews·2026
Same author

Diagnostic accuracy of echocardiography in identifying heart failure related pleural effusions.

Respiratory medicine·2026
Same author

Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregation.

Respiratory research·2025
Same author

Clinical Approach to a Pleural Effusion.

Chest·2025
Same author

New proteomic biomarkers identified in plasma extracellular vesicles in sarcoidosis: a case-control matched study.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Dec 15, 2025

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.8K

Corticosteroid refractory sarcoidosis.

Chananya Goldman1, Marc A Judson1

  • 1Division of Pulmonary and Critical Care Medicine, Albany Medical College, MC-91, 16 New Scotland Avenue, Albany, NY, 12208, USA.

Respiratory Medicine
|July 14, 2020
PubMed
Summary
This summary is machine-generated.

Corticosteroid-refractory sarcoidosis often occurs not due to drug failure, but because symptoms are unrelated to active granulomas. Understanding these causes optimizes patient care and clinical trial stratification.

Keywords:
Corticosteroid toxicityCorticosteroidsMedication adherenceRefractory diseaseSarcoidosis

More Related Videos

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.6K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K

Related Experiment Videos

Last Updated: Dec 15, 2025

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.8K
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

19.6K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K

Area of Science:

  • Pulmonology
  • Immunology
  • Rheumatology

Background:

  • Sarcoidosis is a multisystem inflammatory disease characterized by non-caseating granulomas.
  • Corticosteroids are a cornerstone of sarcoidosis treatment.
  • Some patients exhibit corticosteroid refractoriness, necessitating alternative management strategies.

Purpose of the Study:

  • To review the diverse causes of corticosteroid refractoriness in sarcoidosis.
  • To guide clinicians in managing patients who do not respond to or cannot tolerate corticosteroids.
  • To inform patient stratification for clinical trials.

Main Methods:

  • Literature review of studies on corticosteroid-refractory sarcoidosis.
  • Analysis of reasons for treatment failure, including drug inefficacy and side effects.
  • Discussion of alternative etiologies for persistent symptoms.

Main Results:

  • Corticosteroid refractoriness is rarely due to the drug's failure as an anti-granulomatous agent.
  • The primary reason for apparent refractoriness is often symptoms unrelated to active granulomas.
  • Patient-specific factors, including side effect profiles, contribute to treatment decisions.

Conclusions:

  • Identifying the specific cause of corticosteroid refractoriness is crucial for effective sarcoidosis management.
  • Considering non-granulomatous causes of symptoms can lead to optimized patient care.
  • Accurate etiological diagnosis aids in appropriate patient selection for clinical research.